CDKN2A and acute myeloid leukemia: For example, nucleophosmin (NPM1) is mutated in 50–60% of AML patients with normal karyotype (75,76) and the interaction between NPM1 and cellular tumour antigen p53 (TP53) (77) makes short loop interactions with 25 different proteins such as cell cycle related proteins (CDKN2A, RB1), ribosomal proteins (RPL6, RPS16, RPS13), histone binding (EP300, RBBP4), actin binding (FLNA) and ubiquitin (OTUB1) (78).